New data on the clinical impact of exercise training, fish oils, and statins in heart failure

Physician and Sportsmedicine

Volumn 37, Issue 2, 2009, Pages 22-28

  Lavie, Carl J ^a   O'Keefe, James H ^b   Milani, Richard V ^a   Ventura, Hector O ^a   Mehra, Mandeep R ^c  

^a OCHSNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; Fish oil; Heart failure; Omega 3; Statins

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; ROSUVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; CORONARY RISK; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG MEGADOSE; EXERCISE; FISH; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORTALITY; OBESITY; OXYGEN CONSUMPTION; RECURRENCE RISK; REVIEW; RISK REDUCTION; SUDDEN DEATH; TREATMENT OUTCOME;

ANIMALS; EXERCISE THERAPY; FATTY ACIDS, OMEGA-3; FISH OILS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 70350490037     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2009.06.1706     Document Type: Review

References (41)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-e151.
2. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease - risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925-1932.
3. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488-1496.
4. Johansen H, Strauss B, Arnold JM, Moe G, Liu P. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol. 2003;19(4):430-435.
5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
6. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. Vital Health Stat 13. 2006;159:1-66.
7. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-1450.
8. Keteyian SJ, Miller NH, O'Connor CM, et al; on behalf of HF-ACTION. A dose-response analysis of patients with heart failure enrolled in a controlled trial investigating outcomes of exercise training (HF-ACTION). Paper presented at: American College of Cardiology Scientific Sessions; Orlando, FL; March 29-21, 2009.
9. Tavazzi L, Maggioni AP, Marchioli R, et al; GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-1230.
10. Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-2261.
11. Tavazzi L, Maggioni AP, Marchioli R, et al; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-1239.
12. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107(24):3109-3116.
13. US Department of Health and Human Services. Physical activity and health: a report of the surgeon general. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996.
14. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary coronary prevention. Mayo Clin Proc. 2009;84(4):373-383.
15. Artham SM, Lavie CJ, Milani RV, Chi YW, Goldman CK. Benefits of exercise training in secondary prevention of coronary and peripheral arterial disease. Vasc Dis Prev. 2008;5(3):156-168.
16. Artham SM, Lavie CJ, McMullan PW. Major recent trials in cardiovascular diseases. Postgrad Med. 2009;121(2):15-24.
17. McKelvie RS. Exercise training in patients with heart failure: clinical outcomes, safety, and indications. Heart Fail Rev. 2008;13(1):3-11.
18. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med. 2004;116(10):693-706.
19. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials with chronic heart failure (ExTraMATCH). BMJ. 2004;328(7433):189.
20. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases - a fish tale with growing credibility. In press. J Am Coll Cardiol.
21. Lee JH, OKeefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332.
22. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205-1209.
23. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23-28.
24. Burr ML Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2(8666):757-761.
25. Marchioli R, Barzi F, Bomba E, et al; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-1903.
26. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-1098.
27. Anand RG, Alkadri M, Lavie CJ, Milani RV. The role of fish oil in arrhythmia prevention. J Cardiopulm Rehabil Prev. 2008;28(2):92-98.
28. O'Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate viability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97(8):1127-1130.
29. Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005;45(12):2015-2021.
30. Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2008;56(5):965-974.
31. Yamagishi K, Iso H, Date C, et al; Japan Collaborative Cohort Study for Evaluation of Cancer Risk Study Group. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women. J Am Coll Cardiol. 2008;52(12):988-996.
32. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improved body weight in severe heart failure. J Heart Lung Transplant. 2006;25(7):834-838.
33. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet. 2008;372(9645):1195-1196.
34. Thomas TR, Liu Y, Linden MA, Rector RS. Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia. Appl Physiol Nutr Metab. 2007;32(3)473-480.
35. Smith BK, Sun GY, Donahue OM, Thomas TR. Exercise plus n-3 fatty acids: additive effect on postprandial lipemia. Metabolism. 2004;53(10):1365- 1371.
36. Lavie CJ, Mehra MR. Statins and advanced heart failure - alive but barely breathing after CORONA and GISSI-HF. In press. Congest Heart Fail.
37. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43(4):642-648.
38. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(4):415-426.
39. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115(5):576-583.
40. Mehra MR, Uber PA. Statins and chronic heart failure: a failed hypothesis? In: Mehra MR, ed. Clinical Challenges in Heart Failure. Oxford, United Kingdom: Clinical Publishing Ltd; 2009.
41. Mehra, MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High density lipoprotein cholesterol levels and prognosis in advanced heart failure. In press. J Heart Lung Transplant.